Inclusion Criteria:

          -  Has reached ≥18 years old or the age of the age of majority in their country

          -  Part 1 (dose escalation): Has FLT3-ITD mutant (≥ 3% FLT3-ITD/total FLT3) AML (primary
             AML, secondary, or therapy-related AML), and has treatment failure to prior AML
             therapy or have relapsed after prior AML therapy

          -  Part 2 (dose expansion): Has FLT3-ITD mutant (≥3% FLT3-ITD/total FLT3) AML (primary,
             secondary, or therapy-related AML), and has treatment failure to prior AML therapy or
             have relapsed after prior AML therapy, OR has newly diagnosed AML who are ineligible
             for intensive induction chemotherapy

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (or 3 for
             patients with newly diagnosed AML between 18 and 74 years old)

          -  Has protocol-defined adequate renal, hepatic and cardiac status

          -  Is not pregnant, and if not postmenopausal or a surgically sterile male or female, is
             willing to use a highly effective contraceptive method upon enrollment, during the
             course of the study, and for 6 months following the last dose of investigational drug

          -  Is able and willing to provide protocol-defined bone marrow biopsies/aspirates

        Exclusion Criteria:

          -  Has central nervous system (CNS) involvement of leukemia - patients with a history of
             CNS leukemia may be eligible if the CNS leukemia is adequately controlled (defined as
             no clinical symptoms of CNS disease and at least 2 consecutive lumbar punctures with
             no evidence of disease prior to study enrollment) after discussion and approval from
             the Sponsor

          -  Has acute promyelocytic leukemia (AML subtype M3)

          -  Has uncontrolled or significant cardiovascular disease or QTc interval >450 ms
             (average of triplicate determination)

          -  Has an uncontrolled infection requiring intravenous antibiotics, antivirals, or
             antifungals.

          -  Has known human immunodeficiency virus (HIV) infection, or active hepatitis B or C
             infection based on positive tests during Screening

          -  Has persistent, clinically significant > Grade 1 non-hematologic toxicity from prior
             AML therapies

          -  Has any history or medical condition, metastatic condition, drug/medication use or
             other condition that might, per protocol or in the opinion of the investigator,
             compromise:

               1. safety or well-being of the participant or offspring

               2. safety of study staff

               3. analysis of results